Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.

ABSTRACT:

Background

CFTR modulator therapies have positive clinical outcomes, yet chronic inflammation and bacterial infections persist in people with CF (pwCF). How elexacaftor-tezacaftor-ivacaftor (ETI) fails to improve innate immune signaling responsible for bacterial clearance and inflammation resolution remains unknown.

Methods

We used an unbiased proteomics approach to measure the effect of ETI on inflammatory proteins. Plasma from 20 pediatric pwCF and 20 non-CF (NCF) was collected during routine examination and 3 months after ETI initiation. Protein screening was performed with an inflammation panel (Target 96, Olink^®). Bioinformatics analysis was used to determine changes in protein expression.

Results

There were significantly fewer pulmonary exacerbations

SUBMITTER: Ozuna H 

PROVIDER: S-EPMC11811078 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature